Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $5.05.
A number of research analysts have issued reports on the company. Roth Capital boosted their price target on Sensus Healthcare from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, March 4th. HC Wainwright boosted their price target on Sensus Healthcare from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday, March 8th. Northland Securities upgraded Sensus Healthcare from a “market perform” rating to an “outperform” rating in a research report on Friday, February 26th. Finally, Zacks Investment Research upgraded Sensus Healthcare from a “sell” rating to a “hold” rating in a research report on Wednesday, March 3rd.
NASDAQ:SRTS traded up $0.03 during midday trading on Friday, reaching $3.85. 14,002 shares of the company traded hands, compared to its average volume of 478,475. Sensus Healthcare has a twelve month low of $1.76 and a twelve month high of $6.09. The firm has a market capitalization of $63.47 million, a price-to-earnings ratio of -9.17 and a beta of 0.49. The company has a fifty day moving average price of $4.19 and a 200 day moving average price of $3.52.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Invenomic Capital Management LP raised its stake in shares of Sensus Healthcare by 39.6% in the 4th quarter. Invenomic Capital Management LP now owns 303,766 shares of the company’s stock worth $1,172,000 after buying an additional 86,139 shares in the last quarter. BlackRock Inc. raised its stake in shares of Sensus Healthcare by 2.4% in the 4th quarter. BlackRock Inc. now owns 113,689 shares of the company’s stock worth $439,000 after buying an additional 2,661 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Sensus Healthcare by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 46,283 shares of the company’s stock worth $179,000 after buying an additional 4,163 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Sensus Healthcare by 45.9% in the 4th quarter. Renaissance Technologies LLC now owns 18,434 shares of the company’s stock worth $71,000 after buying an additional 5,800 shares in the last quarter. 7.69% of the stock is currently owned by institutional investors.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures, distributes, and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading: Is a Roth IRA right for you?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.